Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Apr 25 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 4 pages · English

Summary by 6ix AI

The trials, DREAM-ND and DREAM-D, focus on the treatment of anemia in Chronic Kidney Disease patients using Desidustat, a novel HIF-PH inhibitor. The results indicate that Desidustat met primary and secondary endpoints and was well-tolerated in both non-dialysis and dialysis-dependent patients.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange about press release dated 25-Apr-2022 titled Zydus announces publication of ���DREAM-ND��� and ���DREAM-D��� Phase 3 trials of Desidustat in ���American Journal of Nephrology���

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases